glp-1 drugs heart failure receptor agonists as promising anti-inflammatory agents in with preserved ejection fraction | Heart Failure Reviews GLP-1 Agonist Therapy for Advanced

GLP-1 medications are in the spotlight and dont seem to be slowing down any time soon

Affectionately called 'Lizzie, or Gilly' by diabetic patients and marketed as 'Byetta', exenatide was the first slow-release GLP-1 mimic to reach the market (Schuler, Shearin)

This indicates that passing a certain threshold, the potency is just not good enough to produce an observable effect

Here is what actually happened, without the alarm and without the minimization

Current Recommendations GLP-1 medications are not recommended during breastfeeding

GCs reduce peripheral glucose uptake, promote apoptosis in -cells and increase -cell glucagon production, collectively exacerbating hyperglycaemia (69)